Biosimilars Market 2025 Rising Trends and New Technologies Research Report with Teva Pharmaceutical Industries, Pfizer, Biocon, Samsung BioLogics, Mylan N.V., Amgen, Celltrion
A biosimilar is a biological product which is similar to an FDA approved biologic product of another manufacturer. Owing to the complexities associated with development & manufacture of biosimilar products, these are manufactured by companies with highly skillful workforce and deep scientific expertise. The FDA approval process for biosimilar products is rigorous and enables high safety to the end users.
Ask for a Sample of this Report Now at: https://tinyurl.com/y4u2h86e
Biosimilars Market to 2025 - Global Analysis and Forecasts by Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Peptides and Others); and Application (Oncology, Autoimmune Diseases, Chronic Diseases, Blood Disorders, Infectious Diseases, Growth Hormone Deficiency and Others)
• To provide detailed information regarding the major factors (drivers, restraints, opportunities, challenges, and trends) influencing the growth of the global Biosimilars Market
• To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Latin America and the Middle East & Africa)
Some of the key players influencing the market are Teva Pharmaceutical Industries Ltd., Pfizer Inc., Biocon, Samsung BioLogics, Mylan N.V., Amgen Inc., Celltrion, Healthcare Co.,Ltd., Sandoz International GmbH, STADA Arzneimittel AG, Dr. Reddy’s Laboratories Ltd. and others.
The growth of the global biosimilars market can be attributed to the growing demand of pharmaceutical drug supplements, especially for the high priced patented drugs expected to upsurge the growth of the market. Additionally, increasing incidences of chronic diseases add novel opportunities for the global biosimilars market over the forecast period.
The “Global Biosimilars Market Analysis to 2025” is a specialized and in-depth study of the healthcare industry with a focused global market trend. The report aims to provide an overview of global biosimilars market with detailed market segmentation by product, application, end user and geography. The global biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.
On the basis of product the market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, peptides and others. The recombinant non-glycosylated proteins market is further segmented into insulin, recombinant human growth hormone, granulocyte colony-stimulating factor and interferons. The recombinant glycosylated proteins segment is bifurcated into monoclonal antibodies and erythropoietin. The peptides segment is also classified into calcitonin and glucagon. Based on application the market is segmented into oncology, autoimmune diseases, chronic diseases, blood disorders, infectious diseases, growth hormone deficiency and others.
The report provides a detailed overview on the industry including both qualitative and quantitative information. It provides overview and forecast of the global biosimilars based on product and application. It also provides market size and forecast till 2025 for overall biosimilars market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East &Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.
Direct Purchase a Copy of this Report at: https://tinyurl.com/yyt4gltd
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.
We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.
The Insight partners,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market 2025 Rising Trends and New Technologies Research Report with Teva Pharmaceutical Industries, Pfizer, Biocon, Samsung BioLogics, Mylan N.V., Amgen, Celltrion here
News-ID: 1639124 • Views: 354
More Releases from The Insight Partners
Sales Enablement Platform Market 2020 – New Business Strategies, Technological …
The latest report on ‘Sales Enablement Platform Market’ now available at The Insight Partners, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the ‘Sales Enablement Platform Market’. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business. The sales enablement platform market is increasingly gaining traction with the global rise in the startup ecosystem coupled
Digital Experience Platform Market 2020 – New Business Strategies, Technologic …
The latest report on ‘Digital Experience Platform Market’ now available at The Insight Partners, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the ‘Digital Experience Platform Market’. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business. As this platform assist the enterprises to match up with changing customer needs, DXP is gaining high momentum
Digital Banking Platform Market 2020 – New Business Strategies, Technological …
The increasing digital transformation revolution in banking industry presents a massive opportunity for digital banking platform providers as they enable banks to launch digital services faster and enhance the customer experience. In addition to this, the proliferation of smart devices, easy availability of internet, the advancement of IoT, and in Artificial Intelligence have been increasing exponentially, which is further leading to the increasing need of mobile/digital-first strategy among banks. The
Smart Display Market 2020 Top Countries Industry Growth, Size, Share, Competitiv …
The proposed Smart Display Market 2020 report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics. The Smart Display Market sample report includes an exclusive
More Releases for Biosimilars
PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on